Other series studies investigating ONC201 and ONC212 (imipridone) suggested that the upregulation of ISR could promote anti-cancer activity against solid and hematological malignancies [43,44,45,46], and help overcome the resistance to the B-cell lymphoma (BCL)-2 inhibitor venetoclax [47]. The gene discussed is BCL2; the disease is hematologic disorder.